INTRODUCTION
Currently, Nasal drug delivery has been recognized as a very promising route for delivery of therapeutic compounds including biopharmaceuticals. Nasal administration is a logical choice for topical nasal treatments such as antihistamines and corticosteroids. The nasal mucosa has also received attention as a viable means of systemic ad ministration of analgesics, sedatives, hormones, cardiovascular drugs, and vaccines. Conventionally, the nasal route has been used for local delivery of drugs for treating nasal allergy, nasal congestion, or nasal infections. However systemic delivery through the nasal route has recently begun to explore possibilit ies for those requiring a rapid onset of action or necessitating avoidance of severe proteolysis involved in oral administration (e.g., most peptide and protein drugs). Successful attempts to deliver corticosteroid hormones through the nasal route for systemic absorption have triggered further studies in this area.
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Researchers have studied the anatomical and physiological aspects of the nasal membrane, including its vascular nature, as they relate to drug delivery.
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There are three distinct functional regions in the nose-the vestibular, respiratory, and olfactory. Among these, the respiratory region is the most important for systemic drug delivery.
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The respiratory epitheliu m consists of basal, mucuscontaining goblet, ciliated columnar and non-ciliated columnar cell types. 13 The cilia move in a wavelike fashion to transport particles to the pharynx area for ingestion.
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Additionally, the cells in this region are covered by nearly 300 microvilli, providing a large s urface area for absorption. Below the epithelium is the lamina propria. This is where b lood vessels, nerves, serous glands, and mucus secretary glands may be found. The lamina propria also houses a dense network of capillaries, through which drug absorption takes place. The nasal passage epitheliu m is covered by a mucus layer that is renewed every 10 to 15 minutes. 15 The pH of the mucosal secretions ranges from 5.5 to 6.5 in adults and 5.0 and 6.7 in children. 16 The mucus layer entraps particles, which are then cleared fro m the nasal cavity by the cilia. 
Nasal Sprays
The following test parameters are recommended for nasal spray drug products. Appropriate acceptance criteria and validated test procedures should be established for each test parameter.
their respective descriptions as an indication of the drug product integrity. If any color is associated with the formulat ion (either present initially or fro m degradative processes occurring during shelf life) then a quantitative test with appropriate acceptance criteria should be established for the drug product by the manufacturer.
b. Identi ficati on:
A specific identification test(s) is recommended to verify the identity of the drug substance in the drug product. Chro matographic retention time alone is not an adequate method to ensure the identity of the drug substance in the drug product. If the drug substance is a single enantiomer, then at least one of the methods should be specific for this property.
c. Drug Content (Assay):
The assay of drug substance in the entire container should be determined analytically with a stability indicat ing procedure. This test provides assurance of consistent manufacturing (e.g., formu lation, filling, sealing). The acceptance criteria ( assay limits as specified in official books) should be tight enough to ensure conformance in other related attributes (e.g., spray content uniformity). A suitable assay procedure should be designed to address any degradation of the drug substance, adherence of the drug substance to the container and closure components, and the potential effect of formulat ion evaporation and/or leakage.
d. Impuri ties and Degradation Products :
The levels of degradation products and impurities should be determined by means of stability indicat ing procedure(s). Acceptance criteria should be set for individual and total degradation products and impurit ies. For identificat ion and qualification thresholds, refer to the appropriate guidance. All related impurities appearing at levels of 0.1 percent or greater should be specified. Specified impurities and degradation products are those, either identified or unidentified, that are individually listed and limited in the drug product specification.
e. Preservati ve(s) and Stabilizing Exci pient(s) Assay:
If p reservatives, antioxidants, chelating agents, or other stabilizing excip ients (e.g., benzalkoniu m chloride, phenylethyl alcohol, edetate) are used in the formulation, there should be a specific assay for these components with associated acceptance criteria (At a concentration of 0.10 percent or 1.0 milligram per day).
f. Pump Deli very:
A test to assess pump-to-pump reproducibility in terms of drug product performance and to evaluate the metering ability of the pump should be performed. The proper performance of the pump should be ensured primarily by the pump manufacturer, who should assemble the pump with parts of precise dimensions. Pu mp spray weight delivery should be verified by the applicant for the drug product. In general, pump spray weight delivery acceptance criteria should control the weight of the individual sprays to within ±15 percent of the target weight and their mean weight to within ±10 percent of the target weight.
g. S pray Content Uni formity (SCU):
The spray discharged from the nosepiece should be thoroughly analyzed for the drug substance content of mu ltip le sprays from an ind ividual container, among containers, and among batches of drug product. This test should provide an overall performance evaluation of a batch, assessing the formu lation, the manufacturing process, and the pump. The number of sprays per determination should not exceed the number of sprays per single dose. A single dose represents the minimu m nu mber of sprays per nostril specified in the product labeling. To ensure reproducible in vit ro dose collection, the procedure should have controls for actuation parameters (e.g., stroke length, depression force). The test may be performed with units primed following the instructions in the labeling. The amount of drug substance delivered fro m the nosepiece should be expressed both as the actual amount and as a percent of label claim. Th is test is designed to demonstrate the uniformity of med ication per spray (or min imu m dose), consistent with the label claim, d ischarged from the nosepiece, of an appropriate number (n = 10 is recommended) of containers fro m a batch. The primary purpose is to ensure SCU within the same container and among mu ltiple containers of a batch. The following acceptance criteria are reco mmended: 
h. S pray Content Uniformity (SCU) through container life:
The purpose of this test is to assess whether the product delivers the labeled number of fu ll medicat ion sprays meet ing SCU acceptance criteria throughout the life of the nasal spray unit. The test involves determining the SCU fro m the beginning of unit life and at the label claim number of sprays per container for an appropriate nu mber of containers (n = 5 is recommended). The following acceptance criteria are reco mmended. 
i. Spray Pattern and Plume Geometry:
Characterizat ions of spray pattern and plume geomet ry are important for evaluating the performances of the pump and nozzle. Various factors can affect the spray pattern and plume geometry, including the size and shape of the nozzle, the design of the pump, the size of the metering chamber, and the characteristics of the formulation. Spray pattern testing should be performed on a routine basis as a quality control for release of the drug product. However, the characterization of plu me geometry should typically be established during the characterization of the product and is not necessarily tested routinely thereafter. The proposed test procedure for spray pattern, including analytical sampling plans, should be provided in detail to allo w duplicat ion by agency laboratories. For examp le, in the evaluation of the spray pattern, the spray distance between the nosepiece and the collection surface, number of sprays per spray pattern, position and orientation of the collection surface relat ive to the nosepiece, and visualizat ion procedure should be specified. The acceptance criteria for spray pattern should include the shape (e.g., ellipsoid of uniform density) as well as the size of the pattern (e.g., no axis is greater than x millimeters and the ratio of the longest to the shortest axes should lie in a specified range, for example, 1.00-1.20). The spray pattern should be determined, preferab ly by a procedure specific for the drug substance, at different distances (e.g., two) fro m the nosepiece to provide greater discriminatory capability to the test. Variability in the test can be reduced by the development of a sensitive detection procedure and by providing proced ure 502 specific training to the analyst.
j. Droplet Size Distri bution:
For both suspension and solution nasal sprays, the specifications should include an appropriate control for the droplet size d istribution (e.g., 3 to 4 cut-off values) of the delivered plu me subsequent to spraying under specified experimental and instrumental conditions. Appropriate and validated dynamic plu me droplet size analytical procedures should be described in sufficient detail to allow accurate assessment by Agency laboratories (e.g., apparatus and accessories, software version and calculation algorith ms, sample placement, laser trigger condition, measurement range, beam width).
k. Particle Size Distributi on (Suspensions):
For suspension nasal sprays, the specification should include controls for the particle size distribution of the drug substance particles in the formulation. Th is quantitative procedure should be appropriately validated in terms of its sensitivity and ability to detect shifts that may occur in the distribution. The acceptance criteria should control the complete distribution and should reflect the data obtained for the submitted batches (e.g., clinical, preclin ical, biobatch, primary stability, production).
l. Microscopic Eval uation (Sus pensions):
This test, which involves a qualitative and semi quantitative microscopic examination of the suspension formulat ions, is comp lementary to particle size d istribution testing for both release and stability purposes. For example, the examination provides information on the presence of large particles and changes in morphology of the drug substance particles, extent of agglo merates, and crystal growth. Additionally, where changes in the solid state of the drug substance can affect the bioavailability, performance, stability, or other properties of the drug product, microscopic evaluation or other appropriate procedures are recommended to control and monitor changes that are observed on stability.
m. Foreign Particul ates:
For both solution and suspension nasal sprays, there should be validated tests and associated acceptance criteria for foreign particulates. Foreign particulates may orig inate during manufacturing, fro m formu lat ion components, and, in particular, fro m the container and closure components. Levels of foreign particulates in the drug product may increase with time, temperature, and stress.
n. Microbi al Li mits:
The microbial quality should be controlled by appropriate tests and acceptance criteria for total aerobic count, total yeast and mold count, and freedom fro m designated indicator pathogens. Acceptance criteria should be reflective of the data for the submitted batches (e.g., clin ical, preclin ical, biobatch, primary stability, production), but at a min imu m should meet the recommended microbial limits acceptance criteria in USP <1111>, M icrobio logical Attributes for Non-sterile Pharmacopeial Articles. Furthermore, appropriate testing should show that the drug product does not support the growth of microorganis ms and that microbio logical quality is maintained throughout the expiration dating period. For a description of this test, refer to the procedure in USP <61>.
o. Preservati ve Effecti veness:
For nasal sprays that contain a preservative(s), stability testing should include microbial challenge studies performed on the first three production batches of drug product.
p. Net Content and Weight Loss (Stability):
Nasal spray drug products should include acceptance criteria for net content and weight loss on stability. Since storage orientation plays a key role in any weight loss, the drug product should be stored in upright and inverted or upright and horizontal positions to assess this characteristic.
The total net content of all fo rmulat ion components in the entire container should be determined. The net content of each of 10 test containers should be in accordance with the release specification. For a description of this test, refer to the procedure in USP Chapter <755> Min imu m Fill.
q. Leachables (Stability):
The drug product should be evaluated for compo unds that leach fro m elastomeric or plastic co mponents of the container closure system, such as nitrosamines, monomers, plasticizers, accelerators, antio xidants, and vulcanizing agents. The development of appropriate analytical procedures to identify, monitor, and quantify the leached components in the drug product should be done during investigational studies. These validated procedures can, in turn, be used for testing of the drug product throughout the expirat ion dating period. Appropriate acceptance criteria for the levels of leached co mpounds in the formulat ion should be established.
r. pH:
For both solution and suspension nasal sprays, the apparent pH of the formu lation should be tested and an appropriate acceptance criterion established. Lysozyme is found in nasal secretions, which is responsible for destroying certain bacteria at acidic pH. Under alkaline conditions, lysozyme is inactivated and the nasal tissue is susceptible to microbial in fection. It is therefore advisable to keep the formulat ion at a pH of 4.5 to 6.5 keeping in mind the physicochemical properties of the drug as drugs are absorbed in the un-ionized form The osmolality of the fo rmulat ion should be tested and controlled with an appropriate procedure and acceptance developed by manufacturer.
CONCLUS ION:
The quality control of Nasal Spray is critical area where high standards are to be maintained therefore evaluation of different parameters discussed in this review shows strict pharmacovigilance as far as such type of dosage forms are concerned. Impurities and Degradation Products, Preservative(s) and Stabilizing Excipient(s) Assay, Pump Delivery, Spray content uniformity, Spray Content Unifo rmity (SCU) through Container Life, Spray Pattern and Plume Geo met ry, Droplet Size Distribution, Particle size distribution (suspension), Microscopic Evaluation (Suspensions), Foreign Particulates, Microbial limit, Preservative Effectiveness, Net Content and Weight Loss (Stability), Leachables (Stability), PH, Osmo lality. The acceptance criteria for these parameters have been recognized by officials books all over the world. The attempts to deliver corticosteroid hormones through the nasal route for systemic absorption have triggered further studies and strict control over the delivered dosage.
